Antispasmodic Drugs Under Restrictive Watch by KFDA

Published: 2004-12-08 06:56:00

Updated: 2004-12-08 06:56:00

The Korea Food and Drug Administration (KFDA) announced that it would restrict approval, production and sale of seven drugs containing noraminopyrine methane sulfonate calcium (NMSC), which has an antispasmodic effect used for treatment of gastrointestinal, biliary, and urinary tract spasms, among others.

The restrictions, effective December 7, will prevent any current activities surrounding...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.